A double-blind, placebo-control, randomized phase III study to evaluate the efficacy and safety of TAC-202 in patients with perennial allergic rhinitis

Trial Profile

A double-blind, placebo-control, randomized phase III study to evaluate the efficacy and safety of TAC-202 in patients with perennial allergic rhinitis

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Bilastine (Primary) ; Fexofenadine
  • Indications Perennial allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 15 Jun 2015 Status changed from recruiting to completed.
    • 13 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top